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CASE REPORT
DAPSONE HYPERSENSITIVITY SYNDROME IN AN ADOLESCENT DURING
TREATMENT OF LEPROSY
Fábio BUCARETCHI(1,2), Danielly C. VICENTE(1), Ricardo M. PEREIRA(1) & Antonia T. TRESOLDI(1)
SUMMARY
A 12 y old girl was admitted 24 days after start a WHO multidrug therapy scheme for multibacillary leprosy (dapsone,
clofazimine and rifampicin) with intense jaundice, generalized lymphadenopathy, hepatoesplenomegaly, oral erosions, conjunctivitis,
morbiliform rash and edema of face, ankles and hands. The main laboratory data on admission included: hemoglobin, 8.4 g/dL;
WBC, 15,710 cells/mm3; platelet count, 100,000 cells/mm3; INR = 1.49; increased serum levels of aspartate and alanine
aminotransferases, gamma-glutamyl transpeptidase, alkaline phosphatase, direct and indirect bilirubin. Following, the clinical
conditions had deteriorated, developing exfoliative dermatitis, shock, generalized edema, acute renal and hepatic failure,
pancytopenia, intestinal bleeding, pneumonia, urinary tract infection and bacteremia, needing adrenergic drugs, replacement of
fluids and blood product components, and antibiotics. Ten days after admission she started to improve, and was discharged to
home at day 39th, after start new supervised treatment for leprosy with clofazimine and rifampicin, without adverse effects. This
presentation fulfils the criteria for the diagnosis of dapsone hypersensitivity syndrome (fever, generalized lymphadenopathy,
exfoliative rash, anemia and liver involvement with mixed hepatocellular and cholestatic features). Physicians, mainly in geographical
areas with high prevalence rates of leprosy, should be aware to this severe, and probably not so rare, hypersensitivity reaction to
dapsone.
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INTRODUCTION
Dapsone has been broadly used for treatment of leprosy, a wide
variety of dermatological inflammatory diseases such as dermatitis
herpetiformis and chronic bullous dermatosis, Pneumocystis carinii
and malaria prophylaxis1,6,9-11,14-15,24-26. Dapsone therapy may result in a
variety of adverse effects, including hemolytic anemia,
methemoglobinemia, hepatic involvement (hepatocellular or cholestatic
disease, or both), cutaneous involvement (exanthematous eruption,
Stevens-Johnson syndrome or toxic epidermal necrolysis);
agranulocytosis, nephritis, pneumonitis and hypothyroidism1,6,9,11,15-16,18.
Dapsone hypersensitivity syndrome (DHS), firstly described by
ALDDAY & BARNES (1951)1, is a severe and distinct idiosyncratic
adverse reaction, with multiorgan involvement1-5,7-8,10-14,17-25. The present
report describes a near fatal case of DHS in an adolescent.
CASE REPORT
A 12 y old girl was admitted 24 days after start a WHO multidrug
therapy scheme (MDT; dapsone, clofazimine and rifampicin) for
multibacillary leprosy. She was in a satisfactory health condition until
six days before, when fever, malaise, headache and rash developed.
After three days, were noted dark urine and jaundice, and WHO/MDT
was discontinued. Upon hospital admission were observed fever (38.6 oC,
axillary’s temperature), weight = 34 kg, jaundice, oral erosions,
conjunctivitis, generalized lymphadenopathy, hepatoesplenomegaly,
morbiliform rash and edema of face, ankles and hands. The main
laboratory data on admission included: hemoglobin, 8.4 g/dL; WBC,
15,710 cells/mm3, without atypical lymphocytosis or eosinophilia;
platelet count, 100,000 cells/mm3; serum aspartate aminotransferase,
1,013 IU/L [reference value (RV) ≤ 46 IU/L]; alanine aminotransferase
1,406 IU/L (RV ≤ 38 IU/L); gamma-glutamyl transpeptidase, 228 mg/
dL (RV ≤ 35 mg/dL); alkaline phosphatase, 672 IU/L (RV ≤ 447 IU/
L); direct bilirubin, 21.5 mg/dL (RV ≤ 0.2 mg/dL); indirect bilirubin,
5.6 mg/dL (RV ≤ 0.8 mg/dL) and INR = 1.49 (RV ≤ 1.25). Following,
the clinical conditions had deteriorated, developing exfoliative
dermatitis, hypotension, generalized edema, acute renal [creatinine =
1.76 mg/dL (RV ≤ 1.1 mg/dL); urea = 62 mg/dL (RV ≤ 47 mg/dL)] and
hepatic failure (INR = 4.87), pancytopenia, intestinal bleeding, needing
adrenergic drugs, replacement of fluids and blood product components
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(red blood cells, platelets and frozen fresh plasma) and antibiotics due
to pneumonia, urinary tract infection (Escherichia coli and Serratia
marcescens), and bacteremia (Enterococcus faecium). Ten days after
admission she started to improve. Subsequent laboratory studies
revealed normal or negative results: Hepatitis A, B, C; CMV and EBV
serological screens; CD4/CD8 ratio; serum complement (C4) level;
haptoglobine; rheumatoid factor and antinuclear antibody titers. Serum
tests for blood dapsone level, methemoglobin, glucose-6-phosphate
dehydrogenase assay, skin biopsy, treatment with corticosteroids or
dapsone provocation tests were not performed. At day 31st of
hospitalization, she restarted treatment with clofazimine and rifampicin
without any adverse effect, and was discharged to home at day 39th.
Before start these drugs, high IgE levels (> 500 IU/mL; RV < 100 IU/
mL) and eosinophilia (3,364 cells/mm3; RV < 500 cells/mm3) were
observed. The patient remains under supervised treatment for leprosy,
with good outcome.
DISCUSSION
Drugs most frequently causing hypersensitivity syndrome include
anticonvulsants, such as phenyntoin and carbamazepine; sulphonamide
antibiotics and sulfones18. DHS is characterized by the sudden onset
of papular or exfoliative rash, accompanied by fever, malaise and
weakness, followed by jaundice, tenderness of liver and
lymphadenopathy, resembling infectious mononucleosis. Anemia, oral
erosions, conjunctivitis, splenomegaly, eosinophilia, atypical
lymphocytosis, and rise of liver enzymes are other corroborative
findings1-5,7-8,14,17-25. It is important emphasize that all those features
need not necessarily be present10,12,14,18-19,21,25. LETA et al.14, performed
a systematic review of the diagnostic criteria for DHS (33 papers, N =
105 cases, 1956-2001), showing that 59% of these 105 cases could be
classified as complete DHS forms (fever, rash, lymphadenopathy and
hepatitis). This study also revealed that most of the patients with
complete DHS forms presented leprosy (90%), classified as
paucibacillary (71%)14. In general, DHS occur three to six weeks after
start the administration of dapsone, and subside with the cessation of
this drug12,14,18. The course of DHS is variable, but it may last for four
weeks or more12,14,18, being fatal in some cases7-9,14,20,23, with a mortality
rate estimated in 13%14. In addition, intercurrent infections may worse
the clinical outcome8, similar to herein described.
There has been observed an increase in the reports of DHS in the
past few years, and it has been associated with the introduction of WHO/
MDT for leprosy world-wide11,14,19-20. This apparent increase in DHS case
reports depends on multiple factors and are probably related to the
significant decrease of the prevalence of leprosy world-wide after
introduction of MDT - from around 5,4 million to less than 0.53 million
at the beginning of 200326, determining an increase of voluntary reporting
of leprosy patients, associated to improvements in organization of leprosy
controls and awareness among physicians of DHS19.
The real incidence of DHS is not known. According to the review
performed by RAO & LAKSHMI, it probably ranges between 1-4% of
the patients using WHO/MDT19. Brazil is the second most endemic
country of leprosy in the world with a prevalence rate of 4.2/10,000
population26. Among newly detected cases reported of leprosy world-
wide, about 13% are children bellow the age of 1526. Bibliographic
review showed 17 cases of DHS reported by Brazilian authors (Table
1), all of them in patients with leprosy, with two deaths2,3,6,9,13,17,23.
Patient’s age was only cited in the four case reports, being one in a 12
y old child. Although speculative, these data could suggest that DHS
is being sub-notified or not diagnosed.
The pathogenesis of the DHS remains unknown. There is some
evidence to suggest that metabolic differences in the production (eg.,
increased activity or quantity of polymorphic enzymes of cytochrome
P450) and detoxification of reactive metabolites (e.g., glutathione
synthetase deficiency), play an important role in sulphonamide
hypersensitivity reactions18. Production of a toxic metabolite
(hydroxylamine) due to an unbalance between alternative routes of
dapsone metabolism [aceylation (decreased) and hydroxylatylation
(rapid)], have been considered as risk factors for hemolytic anemia4.
The influence of a particular disease state on a susceptibility to a
hypersensitivity reaction is another potential factor, such as the cellular
immunodeficiency observed in patients with lepromatous leprosy, and
history of allergy8,21. Positive lymphocyte stimulation test and
predominantly activated cytotoxic T cells in the dermis of a DHS patient
with skin involvement have also suggested an allergic rather than
idiosyncratic reaction22. The patient’s past medical history revealed
allergy to some cooling drinks. In addition, eosinophilia and high IgE
levels were observed during outcome.
Table 1
Cases of dapsone hypersensitivity syndrome reported by Brazilian authors
Reference (period) Model of study Age (y) Periodical indexed DHS (N) Disease Deaths
Opromolla & Fleury, 199417 CR 67 LILACS 1 Leprosy 1
Gallo, Nery & Garcia, 19959(1986-1994) Adverse effects of WHO/MDT NR LILACS 3/980 Leprosy 0
Brasil et al., 19966(1991-1993) Adverse effects of WHO/MDT NR Medline 0/20,667 Leprosy *
Andrade et al., 19992 CR 12 LILACS 1 Leprosy 0
Barbosa et al., 20003 CR 49 LILACS 1 Leprosy 0
Santos et al., 200223(1990-2001) CS NR Abstract 10 Leprosy 1
Lastória et al., 200413 CR 53 NI 1 Leprosy 0
Total 7 17 2
DHS, dapsone hypersensitivity syndrome; MDT, multidrug therapy; CR, case report; CS, case series; NR, not reported; NI, not indexed; *, two deaths related to
rifampicin.
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Prompt withdrawal of dapsone, supportive measures and minimal
use of other drugs are essential in the management of DHS12. Anecdotal
experience has resulted in the widespread use of corticosteroids in
DHS2-3,10,12,18,21-25, although no controlled studies have been performed
to evaluate it effectiveness. According to some authors, tapering
regimens of systemic corticosteroids are advised because dapsone
persists for up to 35 days in organs via protein binding and enterohepatic
circulation10,12,18,24-25. Preliminary results have pointed that
corticosteroids have not interfered in the outcome of DHS14. However,
methodological limitations preclude conclusions about this feature,
since no analysis were performed considering the correlation among
type and doses of corticosteroids, associated severe infections and
outcome for each case14.
Considering the potential hazards of rechallenge test with
dapsone2,10,12, we accepted our patient’s overall clinical picture
consistent with complete DHS. An isolated adverse reaction to
rifampicin may be excluded, which is known to be hepatotoxic and
nephrotoxic6, since the patient restarted supervised treatment for leprosy
with this drug without adverse effects. However, we cannot rule out
the possibility of interaction between rifampicin and dapsone inducing
the liver damage14.
In conclusion, physicians, mainly in geographical areas with high
prevalence rates of leprosy, should be aware to this potentially fatal,
and probably not so rare, hypersensitivity reaction to dapsone.
RESUMO
Síndrome de hipersensibilidade à dapsona em uma adolescente
durante tratamento de hanseníase
Menina, 12 anos, foi admitida referindo o uso de esquema de
poliquimioterapia preconizado pela OMS para tratamento de hanseníase
forma multicibacilar (dapsona, rifampicina e clofazimina) há 24 dias,
apresentando icterícia, linfadenomegalia generalizada, hepatoesple-
nomegalia, conjuntivite, úlceras orais, exantema morbiliforme e edema
de face, mãos e tornozelo. Os principais achados laboratoriais à
admissão incluíam: hemoglobina, 8,4 g/dl; leucograma, 15.710 céls/
mm3; contagem de plaquetas, 100.000 céls/mm3; RNI = 1,49; aumento
dos níveis séricos da alanino e aspartato aminotransferases, gama-
glutamil transpeptidase, fosfatase alcalina e bilirrubinas. Em seqüência,
ocorreu piora do quadro, desenvolvendo dermatite esfoliativa, choque,
edema generalizado, insuficiências renal e hepática, pancitopenia,
sangramento intestinal, pneumonia, infecção urinária e bacteremia,
necessitando de drogas adrenérgicas, antibióticos, infusão de líquidos
e hemoderivados. Iniciou melhora no 10º dia de internação, recebendo
alta hospitalar no 39º dia, tendo iniciado novo tratamento
supervisionado para hanseníase com rifampicina e clofazimina, sem
efeitos adversos. O caso relatado preenche os critérios para o
diagnóstico de síndrome de hipersensibilidade à dapsona (febre,
dermatite esfoliativa, linfadenopatia, anemia e acometimento hepático
com necrose hepatocítica e colestase). Os médicos, principalmente
em regiões com alta prevalência de hanseníase, devem estar atentos
para esta grave, e provavelmente não tão rara, reação de hipersensi-
bilidade à dapsona.
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